Sort
261,768 grants matching “gene therapy”
Improving the safety and efficacy of cell therapies
$2,011,769Malcolm K Brenner · Baylor College Of Medicine · U54 · FY2006 · HL
Alterations In Lipid Metabolism In The Nervous System By Ethanol
$2,011,598Hee-Yong Kim · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2019 · AA
Proteogenomics for Organ Transplantation: Prediction, Diagnosis, Intervention
$2,011,498Michael Abecassis · Northwestern University At Chicago · U01 · FY2012 · AI
Astrocyte Modulation of Neural Circuit Function and Behavior
$2,011,177Axel Nimmerjahn · Salk Institute For Biological Studies · U19 · FY2025 · NS
Androgen Receptor Action in Castration Resistant Prostate Cancer
$2,010,837Steven P. Balk · Beth Israel Deaconess Medical Center · P01 · FY2014 · CA
Astrocyte Modulation of Neural Circuit Function and Behavior
$2,010,365Axel Nimmerjahn · Salk Institute For Biological Studies · U19 · FY2024 · NS
Gene Therapy for Alzheimer's Disease
$2,010,177Salk Institute For Biological Studies · P01 · FY2005 · AG
Immunotherapy Targeting Tau Aggregate Polymorphs
$2,009,600Rakez Kayed · University Of Texas Med Br Galveston · RF1 · FY2022 · AG
Pharmacogenetics of Nicotine Addiction and Treatment
$2,009,380Neal L Benowitz · University Of California, San Francisco · U01 · FY2006 · DA
RNAi and Epigenetic Control of Higher-Order Chromatin Assembly
$2,009,180Shivinder S Grewal · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Roles of Chromatin-modifying Factors in Epigenetic Control of the Genome
$2,009,180Shivinder S Grewal · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Harvard Genome Characterization Center
$2,009,098Raju S Kucherlapati · Brigham And Women'S Hospital · U24 · FY2012 · CA
Mechanisms and Markers of Prostate Cancer Metastases
$2,008,990University Of Washington · P01 · FY2002 · CA
T-cell receptor gene therapy for cancer
$2,008,917Christian Hinrichs · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Molecular And Pharmacological Studies Of Dopamine Receptors
$2,008,564David Sibley · National Institute Of Neurological Disorders And Stroke · ZIA · FY2024 · NS
Develop an engineered Cas effector for in vivo cell-targeted delivery in the eye to treat autosomal dominant BEST disease
$2,008,538David M Gamm · University Of Wisconsin-Madison · U19 · FY2024 · NS
SPORE in Thyroid Cancer
$2,008,468James A Fagin · Sloan-Kettering Inst Can Research · P50 · FY2016 · CA
SPORE in Thyroid Cancer
$2,008,466James A Fagin · Sloan-Kettering Inst Can Research · P50 · FY2014 · CA
Adeno-associated Virus Biology And Utilization For Gene Transfer
$2,008,334John A Chiorini · National Institute Of Dental & Craniofacial Research · ZIA · FY2013 · DE
Pharmacogenetics in Rural and Underserved Populations
$2,007,290Kenneth E. Thummel · University Of Washington · U01 · FY2011 · GM
Center on Antisocial Drug Dependence: The Genetics of HIV Risk Behaviors
$2,007,203John K Hewitt · University Of Colorado · P60 · FY2013 · DA
Biomarkers of Developmental Trajectories and Treatment in ASD
$2,007,066Susan Y Bookheimer · University Of California Los Angeles · P50 · FY2014 · HD
Molecular And Pharmacological Studies Of Dopamine Receptors
$2,007,060David Sibley · National Institute Of Neurological Disorders And Stroke · ZIA · FY2011 · NS
Comprehensive multimodal analysis of patients with neuroimmunological diseases
$2,006,957Bibiana Bielekova · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
Molecular Diagnosis, Prognosis, and Therapeutic Targets in Lymphoma
$2,006,791Lisa Rimsza · Mayo Clinic Arizona · P01 · FY2019 · CA